Meptyldinocap
Based on 1 Customer Validation
Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts against powdery mildew. Meptyldinocap upregulates the phosphorylation levels of ERK1/2, JNK and p38. Meptyldinocap induces apoptosis and endoplasmic reticulum stress, disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, and triggers mitochondrial dysfunction. Meptyldinocap can be used in studies related to powdery mildew and implantation failure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 131-72-6
- Formule: C18H24N2O6
- Masse moléculaire:364.39
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
MAPK Compound Library
HY-L010
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Endocrinology Compound Library
HY-L047
-
Antifungal Compound Library
HY-L048
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Pyroptosis Compound Library
HY-L059
-
Glutamine Metabolism Compound Library
HY-L064
-
Neuroprotective Compound Library
HY-L070
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Transcription Factor-Targeted Library
HY-L090
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Osteogenesis Compound Library
HY-L131
-
Cuproptosis Compound Library
HY-L133
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Pesticide Compound Library
HY-L183
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Environmental Pollutant Compound Library
HY-L247
-
Lactylation Compound Library
HY-L249
Activité biologique
Meptyldinocap (10-500 nM; 48 h) reduces the viability of pTr and pLE cells in a concentration-dependent manner[2].
Meptyldinocap (150 nM; 48 h) reduces the expression levels of proliferation-related genes PCNA and CDK1 in pTr and pLE cells[2].
Meptyldinocap (150 nM; 24 h) reduces the protein expression levels of proliferation markers PCNA and Ki67 in pTr and pLE cells[2].
Meptyldinocap (50-150 nM; 48 h) increases the proportions of early and late apoptosis in pTr cells; after 48 h of treatment, the 150 nM concentration increases the proportion of early apoptosis in pLE cells, while the 100 and 150 nM concentrations increase the proportion of late apoptosis in pLE cells[2].
Meptyldinocap (50-150 nM; 48 h) induces concentration-dependent cell cycle arrest in pTr cells[2].
Meptyldinocap (150 nM; 24 h) significantly reduces the maximal mitochondrial respiration level of pTr cells; after 24 h of treatment, it shows a non-significant trend of decreased mitochondrial respiration parameters in pLE cells[2].
Treatment with Meptyldinocap (150 nM; 48 h) significantly reduces the mitochondrial membrane potential (MMP) of pTr cells and pLE cells to 207.5% and 271.1%, respectively[2].
Meptyldinocap (50-150 nM; 48 h) upregulates the expression of endoplasmic reticulum stress-related proteins GRP78 and p-eIF2α in pTr cells[2].
Meptyldinocap (50-150 nM; 48 h) reduces the cytoplasmic calcium concentration in pTr cells and pLE cells, thereby disrupting calcium homeostasis[2].
Meptyldinocap (50-150 nM; 30 min) upregulates the phosphorylation levels of ERK1/2, JNK and p38 in pTr cells, thereby altering the MAPK signaling cascade[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:10, 20, 50, 100, 200, 500 nM
-
Incubation Time:48 h
-
Result:Decreased cell viability significantly at 100, 200, and 500 nM in both cell lines.
Reduced cell viability to 50% between 100 and 200 nM for both cell lines.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:150 nM
-
Incubation Time:48 h
-
Result:Reduced PCNA expression to 0.31-fold lower in pTr cells and 0.20-fold lower in pLE cells compared to vehicle-treated controls.
Reduced CDK1 expression to 0.11-fold lower in both cell types compared to vehicle-treated controls.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:150 nM
-
Incubation Time:24 h
-
Result:Reduced PCNA expression in both cell lines.
Reduced the signal intensity of Ki67 in pTr and pLE cells.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:48 h
-
Result:Increased early apoptotic pTr cells to 294.1%, 310.8%, and 310.8% across 50, 100, 150 nM respectively.
Increased late apoptotic pTr cells to 156.6%, 220.9%, and 225.3% across 50, 100, 150 nM respectively.
Showed non-significant increases in early apoptotic pLE cells at 50 and 100 nM, and a significant increase to 310.8% at 150 nM.
Showed non-significant increase in late apoptotic pLE cells at 50 nM, significant increases at 100 nM and 150 nM (225.3%).
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:48 h
-
Result:Induced G1-arrest in pTr cells at 50 nM (G1-phase proportion increased to 80.9%) and 100 nM (G1-phase proportion increased to 84.7%), and G2-arrest at 150 nM (G2-phase proportion increased to 25.4%).
Decreased S-phase cell proportion significantly in pTr cells at 50 and 100 nM.
Induced G1-arrest in pLE cells at all tested concentrations (G1-phase proportion increased to 75.1%, 77.9%, and 77.2% respectively), with significant decreases in S-phase cells at all concentrations.
Reduced CCNB1 expression in pTr cells to 0.73-fold, 0.14-fold, 0.08-fold lower at 50, 100, 150 nM respectively; reduced CCNB1 expression in pLE cells to 0.40-fold and 0.12-fold lower at 100 and 150 nM respectively (no significant change at 50 nM).
Reduced CCND1 expression in pTr cells to 0.76-fold, 0.73-fold, 0.90-fold lower at 50, 100, 150 nM respectively; showed no significant alteration in CCND1 expression in pLE cells.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:48 h
-
Result:Upregulated GRP78 expression to 233.8%, 348.2%, and 678.4% at 50, 100, 150 nM respectively in pTr cells.
Upregulated p-eIF2α expression to 189.5%, 198.0%, and 214.2% at 50, 100, 150 nM respectively in pTr cells.
Upregulated GRP78 expression to 199.9% at 150 nM in pLE cells.
Upregulated p-eIF2α expression to 165.7%, 199.8%, and 230.9% at 50, 100, 150 nM respectively in pLE cells.
-
Cell Line:porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
-
Concentration:50, 100, 150 nM
-
Incubation Time:30 min
-
Result:Upregulated phospho-ERK1/2 levels to 125.5%, 139.8%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-JNK levels to 130.4%, 135.9%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-p38 levels to 124.5%, 150.9%, and 159.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-ERK1/2 levels to 159.4% and 175.0% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-JNK levels to 156.6% and 151.8% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-p38 levels to 181.7%, 163.5%, and 171.1% at 50, 100, 150 nM respectively in pLE cells.
Chemical Information
-
CAS No. 131-72-6
-
Appearance Oil
-
Masse moléculaire 364.39
-
Formule C18H24N2O6
-
Color Light yellow to yellow
-
SMILES
C/C=C/C(OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1C(C)CCCCCC)=O
-
Synonyms
2,4-DNOPC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : ≥ 150 mg/mL (411.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (274.43 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Korean - KR (623 KB)
- Portuguese - PT (623 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang Z, et al. Analytical method for the determination of meptyldinocap as the 2,4-dinitro-octylphenol metabolite in cucumber and soil using LC-MS/MS and a study of the residues in a Chinese cucumber field ecosystem. Pest Manag Sci. 2014;70(1):97-102. [Content Brief]
[2]. Sung E, et al. Meptyldinocap induces implantation failure by forcing cell cycle arrest, mitochondrial dysfunction, and endoplasmic reticulum stress in porcine trophectoderm and endometrial luminal epithelial cells. Sci Total Environ. 2024;924:171524. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.7443 mL | 13.7216 mL | 27.4431 mL | 68.6078 mL |
| 5 mM | 0.5489 mL | 2.7443 mL | 5.4886 mL | 13.7216 mL | |
| 10 mM | 0.2744 mL | 1.3722 mL | 2.7443 mL | 6.8608 mL | |
| 15 mM | 0.1830 mL | 0.9148 mL | 1.8295 mL | 4.5739 mL | |
| 20 mM | 0.1372 mL | 0.6861 mL | 1.3722 mL | 3.4304 mL | |
| 25 mM | 0.1098 mL | 0.5489 mL | 1.0977 mL | 2.7443 mL | |
| 30 mM | 0.0915 mL | 0.4574 mL | 0.9148 mL | 2.2869 mL | |
| 40 mM | 0.0686 mL | 0.3430 mL | 0.6861 mL | 1.7152 mL | |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5489 mL | 1.3722 mL | |
| 60 mM | 0.0457 mL | 0.2287 mL | 0.4574 mL | 1.1435 mL | |
| 80 mM | 0.0343 mL | 0.1715 mL | 0.3430 mL | 0.8576 mL | |
| 100 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6861 mL |
Meptyldinocap Related Classifications
HY-17522 Related Classifications
Powered by Bioz